Association of anti phosphatidyl ethanolamine antibodies and low complement levels in systemic sclerosis patients – results of a cross-sectional study

References

• Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014;111:354–64.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE. Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 2009;61:400–4.
   PubMed Web of Science ®Google Scholar
• Sanna G, Bertolaccini ML, Mameli A, Hughes GRV, Khamashta MA, Mathieu A. Antiphospholipid antibodies in patients with scleroderma: prevalence and clinical significance. Ann Rheum Dis 2005;64:1795–6.
   PubMed Web of Science ®Google Scholar
• Fonollosa V, Selva A, Lima J, Simeon CP, Vilardell M. Anticardiolipin antibodies in systemic sclerosis. J Am Acad Dermatol 1991;25:133–4.
   PubMed Web of Science ®Google Scholar
• Passaleva A, Massai G, Matucci-Cerinic M, Domeneghetti MP, Sharifian J, Lotti T, Cagnoni M, Ricci M. Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease. Autoimmunity 1990;6:283–91.
   PubMed Web of Science ®Google Scholar
• Parodi A, Drosera M, Barbieri L, Rebora A. Antiphospholipid antibody system in systemic sclerosis. Rheumatology (Oxford) 2001;40:111–2.
   PubMed Web of Science ®Google Scholar
• Marie I, Jouen F, Hellot MF, Levesque H. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 2008;158:141–4.
   PubMed Web of Science ®Google Scholar
• Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23: 581–90.
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493–537.
   PubMed Web of Science ®Google Scholar
• Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D. Inter- and intraobserver variability of the total thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281–5.
   PubMed Web of Science ®Google Scholar
• Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, Guiducci S, Conforti ML, Kaloudi O, Nacci F, Sacu O, Candelieri A, Pignone A, Rasero L, Conforti D, Matucci-Cerinic M. Digital ulcers in scleroderma: staging,characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford) 2010; 49:1374–82.
   PubMed Web of Science ®Google Scholar
• Valentini G, D’Angelo S, Della Rossa A, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:904–5.
   PubMed Web of Science ®Google Scholar
• Sulik A, Kowal-Bielecka O, Domysławska I, Chwiećko J, Sierakowski S. The prevalence and clinical significance of antiphospholipid antibodies in the patients with systemic sclerosis – preliminary report. Rocz Akad Med Bialymst 2005;50(Suppl. 1):228–31.
   PubMedGoogle Scholar
• Sato S, Fujimoto M, Hasegawa M, Takehara K. Antiphospholipid antibody in localized scleroderma. Ann Rheum Dis 2003;62:771–4.
   PubMed Web of Science ®Google Scholar
• Devreese KM, Van Hoecke F. Anticardiolipin and anti-β2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles, even for new automated assays. Thromb Res 2011;128:598–600.
   PubMed Web of Science ®Google Scholar
• Sanmarco M. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called ‘seronegative antiphospholipid syndrome’. Autoimmun Rev 2009;9:90–2.
   PubMed Web of Science ®Google Scholar
• Hirmerova J, Ulcova-Gallova Z, Seidlerova J, Filipovsky J, Bibkova K, Micanova Z, Mayer O Jr. Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Clin Appl Thromb Hemost 2010;16: 318–25.
   PubMed Web of Science ®Google Scholar
• Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA. Seronegative antiphospholipid syndrome. Rheumatology (Oxford) 2013;52:1358–67.
   PubMed Web of Science ®Google Scholar
• Boin F, Franchini S, Colantuoni E, Rosen A, Wigley FM, Casciola-Rosen L. Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum 2009; 60:2480–9.
   PubMed Web of Science ®Google Scholar